Creating a Hybrid Care Plan for Heart Failure Patients

Soundos Moualla, MD, FACC, FSCAI
Interventional Cardiology
Dignity Health, Yavapai Regional Medical Center

Congestive heart failure (CHF) results in poor patient outcomes and increases the cost of care particularly with recurrent CHF hospitalizations. Using the CardioCare platform, we have started prospectively cross-matching the CardioCare alerts with hospital heart failure admissions for both aortic stenosis (AS) and mitral regurgitation (MR) patients. This has allowed us to provide better patient care by creating a daily alert system, that improved communication and coordination of care with the heart failure team at Dignity Health, Yavapai Regional Medical Center. This process led to more expeditious care of acutely ill patients, subsequently reducing re-admission rates of patients with congestive heart failure.

In the last year, 224 patients diagnosed with severe mitral regurgitation were also admitted to the hospital with heart failure. With this data, our team created a hybrid care plan among multiple clinical disciplines to increase disease awareness, implement therapeutic interventions based on guidelines, and improve the outcomes of this patient population.

Below is an example of sample data from the CardioCare platform, with reconciled plan of care:

 *Illustrative Data

In addition to the approach above, we plan to further collaborate with the heart failure team to look at patients with retrospective CHF admissions; specifically recurrent CHF admissions, and cross-match with aortic stenosis and mitral regurgitation patients from CardioCare.  We anticipate that we will identify patients with untreated valve pathologies (AS and/or MR) with recurrent CHF exacerbations, who previously have not been under the care of the structural heart or heart failure teams. The aim is to ensure these patients are managed appropriately with guideline directed medical therapy, appropriate valvular therapies, and followed appropriately. It is critical for community structural heart programs to have a multifaceted approach to cardiovascular patient care, striving to improve the standards for physicians, allied health organizations, and most importantly patients.

Related Articles

egnite Research

SGLT2i + GLP-1 RA: A Dynamic Duo in HFpEF?

Heart failure with a preserved ejection fraction (HFpEF) accounts for more than half of all heart failure cases and carries significant morbidity and mortality risk, especially after hospitalization1. Historically, management of the disease is largely focused on comorbidity management and lifestyle modifications, given that available therapies had not demonstrated sufficient impact on hospitalization burden or mortality. In recent years, however, the treatment paradigm for HFpEF has shifted, with a growing emphasis on SGLT2 inhibitors (SGLT2i). Originally developed to lower blood glucose levels in diabetic patients, several clinical trials have firmly established that SGLT2i is also beneficial for patients living with HFpEF2.

Figure 1: Observed Mortality Stratified by GLP-1 RA and/or SGLT2i Prescription
egnite Research

Two-Year Mortality Following Heart Failure Hospitalization in Patients with HFpEF Stratified by SGLT2i and GLP-1 RA Therapy: A Real-World Analysis

BACKGROUND Heart failure with a preserved ejection fraction (HFpEF) is characterized by frequent hospitalizations, and substantial mortality. While historically lacking effective therapies, newer treatments, including SGLT2 inhibitors (SGLT2i) and GLP-1 receptor agonists (GLP-1 RA), have shown potential benefits. However, the clinical course of HFpEF under these therapies remains incompletely characterized,

egnite Research

What the EARLY TAVR Trial Data Could Mean for Already Busy Heart Teams 

On the heels of the exciting EARLY TAVR data and egnite’s Acute Valve Syndrome in Aortic Stenosis study, both led by Dr. Philippe Genereux, we’ve been asked by several cardiovascular (CV) administrators what a potential change in the management of asymptomatic severe aortic stenosis (SAS) patients could mean for their already busy heart teams.